dihydroergotamine (Klaria Pharma)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namedihydroergotamine (Klaria Pharma)
Drug Alias NamedihydroergotamineKL-00204
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1f (5-HT1f) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1f (5-HT1f) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKlaria Pharma Holding AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKlaria Pharma Holding AB
Active IndicationsN/A
Inactive IndicationsMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A